CHICAGO — Satralizumab (Enspryng), a humanized monoclonal antibody, was associated with a significant reduction in relapse risk compared with placebo in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), results from the phase 3 METE... See more
CHICAGO — ALXN1840 (tiomolibdate choline), a first-in-class, investigational copper-binding agent previously known as WTX101, improved clinical outcomes and was generally well tolerated in adults with Wilson disease (WD) in the phase 3 FOCUS trial. WD is ... See more
Nitrous oxide (N2O), commonly known as ‘laughing gas,’ continues to draw interest as a potential rapidly acting treatment for treatment-resistant depression (TRD), but data suggest the larger challenge is whether the drug’s effect is durable enough to mak... See more
There is insufficient or low-quality evidence to suggest cannabinoids are effective at treating most psychiatric conditions and substance use disorders (SUDs), results from one of the largest systematic reviews and meta-analyses to date showed. Investigat... See more
Narrowing the gap between an individual’s biological and chronological age is linked to better biological and chronological age with a positive influence on long-term neurologic outcomes. Using blood-based biomarkers investigators assessed biological age ... See more
